Indication
for the treatment of mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD) in adult patients that are apolipoprotein E ε4 (APOE4) heterozygotes on non-carriers.
Medicine details
- Medicine name:
- donanemab (Kisunla)
- SMC ID:
- SMC2687
- Pharmaceutical company
- Eli Lilly and Company Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Publication due date:
- 12 May 2025
- SMC meeting date:
- 01 April 2025
- Patient group submission deadline:
- 03 March 2025